Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iris Barshack

Showing results (211-220 of 251) with videos related to

Pageof 26
Sort By:
Brain Pathology (Zurich, Switzerland)|July 16, 2008
MiR-92b and miR-9/9* are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumorsDvora Nass, Shai Rosenwald, Eti Meiri, et al.
Cancer Immunology, Immunotherapy : CII|March 22, 2020
TNFR2+ TILs are significantly associated with improved survival in triple-negative breast cancer patientsMaya Dadiani, Daniela Necula, Smadar Kahana-Edwin, et al.
The Journal of Molecular Diagnostics : JMD|September 25, 2010
A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesotheliomaHila Benjamin, Danit Lebanony, Shai Rosenwald, et al.
Breast Cancer Research : BCR|February 5, 2020
ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosisAdi Zundelevich, Maya Dadiani, Smadar Kahana-Edwin, et al.
Cancer Immunology Research|April 19, 2023
MYC Induces Immunotherapy and IFNγ Resistance Through Downregulation of JAK2Ettai Markovits, Ortal Harush, Erez N Baruch, et al.
Molecular Carcinogenesis|September 16, 2022
Divergence of mutational signatures in association with breast cancer subtypeGili Perry, Maya Dadiani, Smadar Kahana-Edwin, et al.
Cancer Discovery|March 1, 2024
Combining TIGIT Blockade with MDSC Inhibition Hinders Breast Cancer Bone Metastasis by Activating Antitumor ImmunityLea Monteran, Nour Ershaid, Ye'ela Scharff, et al.
Breast Cancer Research : BCR|March 14, 2020
Correction to: ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosisAdi Zundelevich, Maya Dadiani, Smadar Kahana-Edwin, et al.
The Journal of Molecular Diagnostics : JMD|July 4, 2012
Classification of the four main types of lung cancer using a microRNA-based diagnostic assayShlomit Gilad, Gila Lithwick-Yanai, Iris Barshack, et al.
The Oncologist|May 24, 2012
A second-generation microRNA-based assay for diagnosing tumor tissue originEti Meiri, Wolf C Mueller, Shai Rosenwald, et al.
Pageof 26

Showing results (211-220 of 251) with videos related to

Sort By:
Pageof 26
Brain Pathology (Zurich, Switzerland)|July 16, 2008
MiR-92b and miR-9/9* are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumorsDvora Nass, Shai Rosenwald, Eti Meiri, et al.
Cancer Immunology, Immunotherapy : CII|March 22, 2020
TNFR2+ TILs are significantly associated with improved survival in triple-negative breast cancer patientsMaya Dadiani, Daniela Necula, Smadar Kahana-Edwin, et al.
The Journal of Molecular Diagnostics : JMD|September 25, 2010
A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesotheliomaHila Benjamin, Danit Lebanony, Shai Rosenwald, et al.
Breast Cancer Research : BCR|February 5, 2020
ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosisAdi Zundelevich, Maya Dadiani, Smadar Kahana-Edwin, et al.
Cancer Immunology Research|April 19, 2023
MYC Induces Immunotherapy and IFNγ Resistance Through Downregulation of JAK2Ettai Markovits, Ortal Harush, Erez N Baruch, et al.
Molecular Carcinogenesis|September 16, 2022
Divergence of mutational signatures in association with breast cancer subtypeGili Perry, Maya Dadiani, Smadar Kahana-Edwin, et al.
Cancer Discovery|March 1, 2024
Combining TIGIT Blockade with MDSC Inhibition Hinders Breast Cancer Bone Metastasis by Activating Antitumor ImmunityLea Monteran, Nour Ershaid, Ye'ela Scharff, et al.
Breast Cancer Research : BCR|March 14, 2020
Correction to: ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosisAdi Zundelevich, Maya Dadiani, Smadar Kahana-Edwin, et al.
The Journal of Molecular Diagnostics : JMD|July 4, 2012
Classification of the four main types of lung cancer using a microRNA-based diagnostic assayShlomit Gilad, Gila Lithwick-Yanai, Iris Barshack, et al.
The Oncologist|May 24, 2012
A second-generation microRNA-based assay for diagnosing tumor tissue originEti Meiri, Wolf C Mueller, Shai Rosenwald, et al.
Pageof 26